Benedetti Rosaria, Chianese Ugo, Papulino Chiara, Scisciola Lucia, Cortese Mirko, Formisano Pietro, Del Gaudio Nunzio, Cabaro Serena, D'Esposito Vittoria, Pesapane Ada, Conte Mariarosaria, Signoriello Giuseppe, Barbieri Michelangela, Altucci Lucia, Paolisso Giuseppe
Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Program of Medical Epigenetics, Vanvitelli Hospital, Naples, Italy.
Eur J Heart Fail. 2025 May;27(5):844-856. doi: 10.1002/ejhf.3566. Epub 2025 Jan 14.
Hyperglycaemic conditions increase cardiac stress, a common phenomenon associated with inflammation, aging, and metabolic imbalance. Sodium-glucose cotransporter 2 inhibitors, a class of anti-diabetic drugs, showed to improve cardiovascular functions although their mechanism of action has not yet been fully established. This study investigated the effects of empagliflozin on cardiomyocytes following high glucose exposure, specifically focusing on inflammatory and metabolic responses.
A three-part strategy was formulated: (i) a meta-analysis of selected randomized clinical trials was carried out to assess the anti-inflammatory effects of empagliflozin in diabetic patients; (ii) the impact of empagliflozin on human cardiomyocyte AC16 cells exposed to normal (5 mM) and high (33 mM) glucose concentrations for 2 and 7 days was explored by evaluating gene expression and protein levels of pivotal markers associated with cardiac inflammation, stress, endoplasmic reticulum damage, and calcium modulation; (iii) in silico data from bioinformatic analyses were exploited to construct an interaction map delineating the potential mechanism of action of empagliflozin on cardiac tissue. Empagliflozin reversed high-glucose mediated alterations at the transcriptional level, decreasing inflammatory, metabolic, and aging signatures. Specifically, in vitro experiments on human cardiomyocytes, meta-analyses of clinical data on inflammatory biomarkers from diabetic peripheral blood samples, and sequencing of pathological human heart tissues, all support that empagliflozin exerts anti-inflammatory effects both systemically and directly in cardiac tissue, on cardiomyocytes.
Our study provides insights based on robust mechanistic data for optimizing heart failure management and highlights the intricate interplay between diabetes, inflammation, aging, and cardiovascular health.
高血糖状况会增加心脏应激,这是一种与炎症、衰老和代谢失衡相关的常见现象。钠-葡萄糖协同转运蛋白2抑制剂是一类抗糖尿病药物,尽管其作用机制尚未完全明确,但已显示出可改善心血管功能。本研究调查了恩格列净在高糖暴露后对心肌细胞的影响,特别关注炎症和代谢反应。
制定了一个分为三个部分的策略:(i)对选定的随机临床试验进行荟萃分析,以评估恩格列净对糖尿病患者的抗炎作用;(ii)通过评估与心脏炎症、应激、内质网损伤和钙调节相关的关键标志物的基因表达和蛋白水平,探讨恩格列净对暴露于正常(5 mM)和高(33 mM)葡萄糖浓度2天和7天的人心肌细胞AC16细胞的影响;(iii)利用生物信息学分析的计算机数据构建一个相互作用图谱,描绘恩格列净对心脏组织的潜在作用机制。恩格列净在转录水平上逆转了高糖介导的改变,降低了炎症、代谢和衰老特征。具体而言,对人心肌细胞的体外实验、对糖尿病外周血样本中炎症生物标志物的临床数据的荟萃分析以及对病理性人心脏组织的测序,均支持恩格列净在全身和心脏组织中对心肌细胞均具有抗炎作用。
我们的研究基于有力的机制数据为优化心力衰竭管理提供了见解,并突出了糖尿病、炎症、衰老和心血管健康之间复杂的相互作用。